BioSpace News Archive

Spero Therapeutics, Inc. announced that on September 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 110,000 restricted stock unit awards to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

INVO Bioscience, Inc. announced that its special meeting of shareholders on September 29, 2023 was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023.

NANOBIOTIX announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with locally advanced head and neck cancer—at the 65th Annual Meeting of the American Society for Radiation Oncology.

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on September 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in September 2023.

Moderna, Inc. has become aware that TRC Capital Investment Corporation has amended its unsolicited “mini-tender” offer to purchase up to 1,000,000 shares of Moderna’s common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer.

Bloom Burton & Co. (“Bloom Burton”) is pleased to announce Stephen Dilly, former Chief Executive Officer of Sierra Oncology, as the recipient of the 2023 Bloom Burton Award.

Regel Therapeutics announced that based upon the groundbreaking work of its Co-Founder and Chief Scientific Officer Dr. Navneet Matharu, it has been selected to receive $1 Million in non-dilutive funding from the HS Chau Foundation through the Women in Enterprising Science Program at the Innovative Genomics Institute founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna.

ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).